594839-88-0
>98%
308
FX-1006; 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; tafamidisum
- Data sheet: View or download
- MSDS: View or download
Tafamidis is a potent kinetic stabilizer of transthyretin (TTR). Tafamidis binds selectively and with negative cooperativity (Kd values ∼2 nM and ∼200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer and kinetically stabilizes TTR. It prevents tetramer dissociation, the rate-limiting step in TTR misfolding and amyloidogenesis. Tafamadis also binds and stabilizes patient-derived amyloidogenic variants of TTR, including kinetically and thermodynamically less stable mutants. It is approved for the treatment of cardiomyopathy caused by transthyretin mediated amyloidosis in adults.
-20°C
